| 000 | 03568cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032252.0 | ||
| 008 | 190502s2018 ua h f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.29.Ph.D.2018.Am.E | ||
| 100 | 0 | _aAmira karam Mahmoud | |
| 245 | 1 | 0 |
_aEvaluation of the osteomodulator and cardiovascular protective effect of in combination with risedronate, raloxifene and strontium ranelate in an osteoporotic rat model / _cAmira karam Mahmoud ; Supervised Soheir Abou Elazm Diab , Ghada Mohamed Abdelzaher Hashem , Mira Farouk Youssef |
| 246 | 1 | 5 | _aتقييم التأثير المحور لأستجابة خلايا العظام و الواقى للقلب والأوعيه الدمويه للسيمفاستاتين منفردا و بالأضافه لأى من ريزيدرونات: رالوكسيفين و سترانشيوم رانيلات على نموذج هشاشة العظام المستحدث فى الجرذان البيضاء |
| 260 |
_aCairo : _bAmira karam Mahmoud , _c2018 |
||
| 300 |
_a194 P. : _bfacsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pharmacology | ||
| 520 | _aBackground: Osteoporosis is one of the deleterious side effects of long-term glucocorticoid therapy. The side-effects of the currently available osteoporotic therapies and their ability to increase bone mass is relatively small not more than 2% per year so, there is a need for novel drug therapies for the treatment of osteoporosis. Evidence that osteoporosis and cardiovascular diseases are positively correlated. Therefore, the attention has driven toward the importance of possible synergism that might occur from combination of anti resorpative medications with simvastatin. Aim of the work: Assess the osteomodulatory and cardio vascular protective effect of Simvastatin, residronate, strontium ranelate and raloxifene separately and their combination with simvastatin in rat model of glucocorticoid induced osteoporosis. Methodology: A 72 Mature healthy albino rats of both sex are randomly allocated into 9 main groups and received drugs for 6weeks by oral gavage. G1: Normal control group,G2:osteoprotic treated group received prednisolone (pred) at 30 mg/kg per 2 days ,G3:Simvastatin(Sim)- treated group received simvastatin at10mg/kg/day,G4:Residronate (Residr)- treated group received residronate at 1mg/kg/day), G5: Strontium (SR)-treated group received strontium at 600mg/kg/day,G6:raloxifene (RAL)-treated group, received raloxifene at 1.25mg/kg/day, G7:SIM+Residr-treated group,G8:Sim +SR treated group and G9:Sim +RAL treated group. At the end of 6 weeks ,all studied groups were assessed pharmacologically by measurement of mean arterial blood pressure (MAP), ECG and echocardiography, biochemically, by measurement of serum Ca, P, osteocalcin(OCN), bone specific alkaline phosphatase (BSAP),ALT and AST. Histologically by assessment of bone cortical thickness, histopathological scoring and bone mineral density by DEXA scan was also recorded | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAntiresorpative medication | |
| 653 | 4 | _aGlucocorticoids | |
| 653 | 4 | _aSimvastatin | |
| 700 | 0 |
_aGhada Mohamed Abdelzaher Hashem , _eSupervisor |
|
| 700 | 0 |
_aMira Farouk Youssef , _eSupervisor |
|
| 700 | 0 |
_aSoheir Abou Elazm Diab , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c71729 _d71729 |
||